Guntern Takes Lead At Medicines For Europe

Sandoz Executive Becomes Interim President After Teva’s Stoller Completes Two-Year Term

Sandoz’s Rebecca Guntern has been named as interim president of Medicines for Europe for a three-month term, after Teva’s Christoph Stoller stepped down at the end of his two-year tenure.

Rebecca Guntern, of Sandoz
Rebecca Guntern has taken over as interim president of the association • Source: Sandoz

European off-patent industry association Medicines for Europe has announced the appointment of Sandoz’s head of Europe, Rebecca Guntern, as the body’s president for an interim term of three months, ahead of the formal election and appointment of a permanent president in 2022.

Guntern’s term begins today after former president Christoph Stoller of Teva stepped down following the completion of his two-year tenure....

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Leadership

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C5

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C4

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

Wagner Adds Germany To Role As Stada Simplifies Structure

Steffen Wagner has taken over as Stada’s head of Germany, adding to his existing responsibilities in Europe, after Eelco Ockers stepped down from the role. Ockers’ departure comes as German generics giant Stada restructures its business to bring its branded and consumer health interests into closer alignment as part of a more streamlined model.

More from Generics Bulletin

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C10

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.